Merck Canada has taken what it called a “critical step” toward making its approved therapy Winrevair (sotatercept-csrk) — which works to improve exercise capacity and reduce the risk of clinical worsening events in people with pulmonary arterial hypertension (PAH) — accessible to eligible patients in the country. The…
News
Merck is planning a Phase 3 trial testing Winrevair (sotatercept-csrk) in people with combined post- and precapillary pulmonary hypertension (CpcPH) due to heart failure with preserved ejection fraction (HFpEF). CpcPH is a form of pulmonary hypertension due to left heart disease, marked by elevated blood pressure in the vessels…
Researchers in the U.S. have found that exposure to low oxygen levels — known as hypoxia — early in life can cause pulmonary hypertension (PH) by permanently altering lung blood vessel development. The team used a new mouse model they designed to better reflect a severe form of PH…
CM5480, an experimental therapy being developed by Calcimedica, improved blood flow and heart-function measures in a rat model of pulmonary arterial hypertension (PAH), a new study reports. The therapy was helpful when used on its own and provided additional benefits when combined with two currently available…
Cereno Scientific is seeking a green light from the U.S. Food and Drug Administration (FDA) to launch a global clinical trial testing its oral therapy CS1 — a repurposed drug now used for treating seizures — in people with pulmonary arterial hypertension (PAH). In PAH, the company hopes the…
This article is provided by our partner, the American Lung Association. It has been reviewed by Bionews for accuracy and relevance. The views and opinions expressed are those of the author and do not necessarily reflect the views of Bionews or Pulmonary Hypertension News. How often do you think…
Researchers have identified distinct genetic changes tied to the severity of idiopathic pulmonary arterial hypertension (IPAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Data showed that the expression (activity) of the ABCA3 gene was lower in IPAH patients, while that of the SMAD9 gene was increased in CTEPH, particularly…
The first clinical site is now active for a global Phase 3 study that will evaluate Gossamer Bio’s therapy candidate seralutinib in people with pulmonary hypertension associated with interstitial lung disease (PH-ILD). Dubbed SERANATA, the study aims to enroll about 480 people with PH-ILD, ages 18 to 80. No…
Treprostinil may help manage pulmonary hypertension (PH) in children who’ve undergone Fontan surgery for congenital heart defects, according to a study in China. The treatment was associated with lower mean pulmonary arterial pressure (PAP) and improved oxygenation — oxygen delivery to tissues. The therapy was well tolerated, with no…
The investigational treatment TX45 may help improve heart function and circulatory health in people with pulmonary hypertension and heart failure with reduced ejection fraction (PH‑HFrEF). That’s according to new early clinical trial data announced by developer Tectonic Therapeutic, which tested a single intravenous (into-the-vein) dose of the therapy…
The advocacy organization Phaware has launched a new mobile app to help people living with pulmonary hypertension (PH) better manage their condition. Called Heart Works – phaware, the app is available on iPhone, Apple Watch, and Android devices — launching just in time for…
The U.S. Food and Drug Administration (FDA) has approved updated prescribing information for Merck‘s Winrevair (sotatercept-csrk) that more specifically details how the pulmonary arterial hypertension (PAH) therapy reduces the risk of serious complications. Winrevair was approved by the FDA last year to improve…
